回生口服液治疗原发性肝癌临床疗效的系统评价

Systematic review of the clinical efficacy of Huisheng Oral Liquid in the treatment of primary liver cancer

目的:系统评价回生口服液联合其他方法与单独使用其他方法相比在治疗原发性肝癌的优越性,为临床实践提供循证依据,为安全、合理用药提供参考。方法:计算机检索中国期刊全文数据库、维普数据库、万方数据库,纳入回生口服液治疗原发性肝癌的随机对照试验,包括对近期疗效、生活质量、不良反应的比较。检索时间为各数据库建库至2018年10月,对纳入文献进行数据提取和质量评价,采用Cochrane系统评价手册5.1.0进行偏倚风险评价,采用Rev Man 5.3软件进行Meta分析,利用改良Jadad量表对纳入研究的文献进行质量评价,应用RevMan5.3软件进行数据分析。结果:本研究共纳入11个随机对照试验,共753例患者,纳入文献均为低质量研究。Meta分析结果显示:与对照组相比,回生口服液联合其他方法可提高治疗原发性肝癌的近期疗效[(P<0.00001),0R=2.20,95%Cl(1.62,2.99)],改善患者的生活质量[(P<0.00001),0R=4.34,95%Cl(2.72,6.93)],降低治疗的不良反应[(P<0.00001),0R=0.28,95%Cl(0.18,0.42)],以上差异均有统计学意义。结论:临床上使用回生口服液联合其他方法治疗原发性肝癌患者具有一定的减毒增效的作用,可提高治疗效果,改善患者生活质量,降低不良反应。基于当前对回生口服液的研究依据、纳入的研究样本数量和样本的研究质量的局限,回生口服液治疗原发性肝癌的长期疗效及安全性仍然需要更多高质量、大样本、多中心的随机对照研究来加以验证。

Objective:To evaluate the advantages of Huisheng Oral Liquid(回生口服液)combined with other methods in the treatment of primary liver cancer compared with other methods,to provide evidence basis for clinical practice and reference for safe and rational drug use.Methods:The full-text database,Weipu database and Wanfang database of Chinese periodicals were searched by computer,including the randomized controlled trial of Huisheng Oral Liquid on primary liver cancer,the comparison of short-term efficacy,quality of life and adverse reactions.The retrieval time was from the inception of the databases to October 2018.Data extraction and quality evaluation were conducted for the included literature.Risk of bias was assessed using Cochrane 5.1.0,Meta analysis was performed using RevMan5.3,literature quality was assessed using the modified Jadad scale,and data were analyzed using RevMan5.3.Results:A total of 11 randomized controlled trials were included in this study,involving 753 patients.The included literature was all low-quality studies.Meta analysis results showed that:compared with control group,the Huisheng Oral Liquid with other therapy methods of primary liver cancer can improve the near future curative effect(P<0.00001),and 0R=2.20,95%CI(1.62,2.99)],and improve the patient's quality of life(P<0.00001),and 0R=4.34,95%CI(2.72,2.72),reduce the adverse reaction of treatment(P<0.00001),and 0R=0.28,95%CI(0.18,0.42).Conclusion:Huisheng Oral Liquid combined with other methods has a certain effect of reducing toxicity and increasing efficacy in patients with primary liver cancer.It can improve the effect of treatment,promote the quality of life of patients and reduce adverse reactions.Based on the current research basis of Huisheng Oral Liquid,the number of included research samples and the limitations of the research quality of samples,the long-term efficacy and safety of Huisheng Oral Liquid in the treatment of primary liver cancer still need to be verified by more high-quality,large-sample,multi-center randomized controlled studies.